| This week's sponsor is Patheon, part of Thermo Fisher Scientific. | |  | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications.
Editor's Note
The J.P. Morgan Healthcare Conference whirlwind has come and gone for another year, leaving behind more headlines, hallway buzz and general chatter than ever. So much, in fact, that our annual JPM special issue couldn’t contain even half our coverage, and the daily roundup of updates overflowed. In this follow-up edition, we’re recapping the conference with expert analysis, a best-of roundup of our on-the-ground reporting, our final dispatches from San Francisco—don’t miss the Novartis AI interview—and a few of the most-read stories of the week. And for those of you who couldn’t make our annual breakfast event in person, you’ll find our coverage of those two expert panels moderated by FierceBiotech and FiercePharma editors. So long, San Francisco, for another year. — Tracy Staton
| |
|
Featured Story | | | Thursday, January 10, 2019 Executives at this year's J.P. Morgan Healthcare Conference agreed the tone was somewhere between gloom and sunshine—“much better than I would have anticipated,” Neurocrine CEO Kevin Gorman said. |
|
|
| This week's sponsor is Patheon, part of Thermo Fisher Scientific. | |  | |
Top Stories Of The Week Friday, January 11, 2019 Big deals, attempts at decent deals and impending IPOs—sure, the J.P. Morgan Healthcare Conference was awash in deal buzz as well as the occasional rainfall. But that's far from all the talk that came out of meeting rooms, restaurants and hotel lobbies. Here's our top coverage from FierceBiotech and FiercePharma, with a couple of extras thrown in. Wednesday, January 9, 2019 SAN FRANCISCO—We certainly like to offer a full breakfast here at FierceBiotech, especially at the J.P. Morgan Healthcare Conference, where attendees have probably had to get a second mortgage for a three-day hotel stay. Thursday, January 10, 2019 Despite Trump’s furor, Congress’ scrutiny and public uproar, drug prices—at least list prices—are still going up. There are ideas on all sides—as a FiercePharma panel talk at the J.P. Morgan Healthcare Conference showed—but neither the government nor private payers nor the industry can come up with an effective solution alone. Thursday, January 10, 2019 The FDA shutdown is holding up human trials for Aimmune's egg allergy program and may delay approval for its oral immunotherapy for peanut allergy. Wednesday, January 9, 2019 Artificial intelligence is a big buzzword in R&D right now, but at Novartis, it's hard at work in the sales department, too. And U.S. chief Paul Hudson was scouting health-tech companies at the J.P. Morgan Healthcare Conference for a major "tech disruption" in pharma this year. Thursday, January 10, 2019 SAN FRANCISCO—It’s been a busy year for Propeller Health, culminating at JPM this year with the closing of its $225 million buyout by ResMed and a new partnership with Walgreens that allows patients to refill their prescriptions through their smartphone app. Tuesday, January 8, 2019 The FDA is creating an office of drug development science to cut the cost of bringing new medicines to patients, BioCentury reports. Staff at the office will create tools that sponsors and the FDA can use to streamline the development and regulatory assessment of drugs. Tuesday, January 8, 2019 There’s a reason Merck hasn’t made a big acquisition lately. And it’s not because it doesn’t want to. “We’re very active,” CEO Ken Frazier said during a Monday afternoon fireside chat at the J.P. Morgan Healthcare Conference. What's the holdup, then? Monday, January 7, 2019 Eli Lilly will buy Loxo for $235 per share in cash—a 68% premium over Loxo’s most recent closing price. Announced as JPM kicked off, the deal gives Lilly the high-priced TRK inhibitor Vitrakvi and three other targeted cancer drugs. Tuesday, January 8, 2019 It feels like there’s a little more than just precipitation in the air at the J.P. Morgan Healthcare Conference this year: a dash of optimism and cash. Resources Presented by: Aprecia Get ahead of looming challenges in the market that include both generic products and new branded drugs. Sponsored by: Oracle Health Sciences New infographic shows trends in clinical development and the impact on randomization and trial supply management technology (RTSM). Sponsored by: Veeva Reduce the effort to create submissions and track registrations with a move to unified RIM. Watch the on-demand webinar. Sponsored by: DocuSign Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin? Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. |
|
